Jubilant Life Sciences Seeks Nod To Roll Out Remdesivir Tablet
Noida-based Jubilant Life Sciences plans to launch remdesivir in a tablet form. The antiviral drug, which is being used to treat Covid-19 patients, is currently administered intravenously.The pharmaceutical company has sought permission of the Drugs Controller General of India (DCGI) to launch remdesivir in a tablet form. In a meeting held on August 25, the company had presented its proposal to the DCGI.The company has given bioavailability protocol to the subject expert committee (SEC), which has been set up to evaluate proposals related to Covid-19, according to the minutes of the meeting, a copy of which was seen by ET.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
